Test Price
2,800 AED✅ Home Collection Available
FERMT3 Gene Leukocyte Adhesion Deficiency Type 3 (LAD3) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary: Clinically validated genetic test with 99.9% diagnostic sensitivity via ISO 15189 accredited next-generation sequencing. VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily (8 AM – 11 PM). Post-test telephonic clinical guidance included. Insurance billing verification via WhatsApp +971 54 548 8731.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS processing.
- Premium Logistics: VIP mobile phlebotomy and ISO-certified cold-chain home collection (paid service).
- Clinical Guidance: Telephonic post-test interpretation with board-certified genetic specialist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FERMT3 NGS test identifies pathogenic variants in the FERMT3 gene responsible for Leukocyte Adhesion Deficiency Type 3 (LAD3), a severe primary immunodeficiency disorder characterised by recurrent infections, bleeding tendency, and impaired wound healing. Early molecular diagnosis is critical for haematopoietic stem cell transplantation planning and lifelong management. This test utilises next-generation sequencing (NGS) covering the full coding region, splice sites, and copy number variations (CNVs).
| Feature | Our FERMT3 NGS Test | Closest Alternative (Targeted Sanger) |
|---|---|---|
| Precision | 99.9% (full gene coverage + CNV detection) | ~99.0% (limited to known exons) |
| Methodology | Next-Generation Sequencing (NGS) – full gene coverage | Sanger sequencing of selected hotspot regions |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a clinical geneticist, I recognise the profound implications of diagnosing Leukocyte Adhesion Deficiency Type 3. The FERMT3 NGS test offers a definitive molecular answer required for life-saving interventions. However, results must always be correlated with complete blood counts, flow cytometry, and clinical phenotype. Genetic counselling before and after testing remains essential for informed decision-making.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Note
Do not discontinue or modify prescribed therapies—including prophylactic antibiotics, immunoglobulin replacement, or immunosupportive medications—without consulting your managing haematologist or immunologist. The genetic test result does not replace ongoing clinical care.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active severe infection requiring hospitalisation, uncontrolled bleeding, or inability to provide adequate blood/DNA sample.
- Emergency Red Flags – Seek immediate care if: Sudden high fever with rigors, acute gum/nose/GI bleeding, signs of sepsis (lethargy, poor perfusion), or new-onset neurological deficits.
- Post-Test: Await formal genetic counselling interpretation before making any major clinical decisions.
Patient FAQ & Clinical Guidance
1. What is the FERMT3 LAD3 genetic test used for?
This test detects mutations in the FERMT3 gene that cause Leukocyte Adhesion Deficiency Type 3, a primary immunodeficiency with bleeding tendency. It confirms the diagnosis and guides treatment decisions such as stem cell transplantation.
2. How should I prepare for the FERMT3 NGS test?
No fasting or medication adjustments are required. A mandatory clinical history review and genetic counselling session must be completed before sample collection. Please bring any prior medical records or family pedigree charts.
3. When can I expect the results, and how will they be delivered?
Results are available within 3 to 4 weeks. They are delivered via a secure patient portal, followed by a scheduled telephonic clinical guidance session with a genetics specialist.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed in encrypted DHA‑approved facilities. Clinical safety and patient consent align with Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 15189:2022 accreditation for molecular diagnostics. Corporate entity: DNA Labs UAE, DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | FERMT3 Gene Leukocyte Adhesion Deficiency Type 3 (LAD3) Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or one drop blood on FTA card – VIP mobile phlebotomy & cold-chain home collection available |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene coverage with CNV detection |
| ICD-10-CM Code | D72.0 (Genetic disorders of leukocytes) |
| LOINC Code | 49863-9 (FERMT3 gene mutation analysis) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians